EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myeloma
The European Hematology Association’s annual congress (EHA 2021) is one of the most important haematology congresses in Europe and it is taking place from 9 to 17 June. Results from Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed myeloma has been presented.